ENDRA Life Sciences (NDRA) Cash from Operations (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Cash from Operations for 11 consecutive years, with -$927560.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 16.71% year-over-year to -$927560.0 in Q2 2026; TTM through Jun 2026 was -$4.8 million, a 13.56% increase from a year earlier, with the FY2025 full-year figure at -$5.2 million, up 29.97% from the prior year.
• Cash from Operations was -$927560.0 for Q2 2026 at ENDRA Life Sciences, up from -$1.1 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$927560.0 in Q2 2026 and troughed at -$3.3 million in Q2 2022.
• A 5-year average of -$2.1 million and a median of -$2.1 million in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations decreased 19.13% in 2022 and soared 46.54% in 2025, its largest moves.
• Over 5 years, Cash from Operations stood at -$3.1 million in 2022, then rose by 29.6% to -$2.2 million in 2023, then surged by 30.3% to -$1.5 million in 2024, then fell by 6.33% to -$1.6 million in 2025, then jumped by 42.45% to -$927560.0 in 2026.
• The last three Cash from Operations figures came in at -$927560.0 (Q2 2026), -$1.1 million (Q1 2026), and -$1.6 million (Q4 2025), per Business Quant data.